First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an option for patients with type II diabetes who are hesitant to use injectable treatments.

by Chloe Harman
The starting dose of Rybelsus is 3mg once daily. After one month, the dose should be increased to 7mg once daily; if needed, it can be further increased to 14mg once daily. | GETTY IMAGES
The starting dose of Rybelsus is 3mg once daily. After one month, the dose should be increased to 7mg once daily; if needed, it can be further increased to 14mg once daily. | GETTY IMAGES

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package